Foghorn Therapeutics Announces Clinical Data From Phase 1 Study Of FHD-286 In Metastatic Uveal Melanoma To Be Presented At ESMO Congress
Portfolio Pulse from Benzinga Newsdesk
Foghorn Therapeutics Inc. (NASDAQ:FHTX) announced that clinical data from the Phase 1 study of FHD-286 in metastatic uveal melanoma will be presented at the ESMO Congress 2023. FHD-286 is a potent, selective, allosteric, and orally available small-molecule, enzymatic inhibitor of BRG1 and BRM, two key regulators within the chromatin regulatory system. In pre-clinical studies, FHD-286 has shown anti-tumor activity across a broad range of malignancies.
October 13, 2023 | 12:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Foghorn Therapeutics' announcement of presenting clinical data from the Phase 1 study of FHD-286 at the ESMO Congress 2023 could potentially boost investor confidence in the company's research and development capabilities.
The announcement of presenting clinical data at a prestigious event like the ESMO Congress is a positive development for Foghorn Therapeutics. It indicates progress in their research and development, which could potentially lead to new product offerings in the future. This could boost investor confidence in the company's capabilities and prospects, potentially leading to a positive impact on the stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100